US FDA Breast Implant Postapproval Studies: Long-term Outcomes in 99,993 Patients

Keyphrases

• US FDA 100%
• Post-approval Changes 100%
• Breast Implants 100%
• Silicone 75%
• Long-term Safety 50%
• Normative Data 50%
• Silicone Implant 50%
• Capsular Contracture 50%
• Standardized Incidence Ratio 50%
• Long-term Implants 50%
• Systemic Damage 50%
• Magnetic Resonance Imaging 25%
• Melanoma 25%
• Efficacy Outcomes 25%
• Number of Patients 25%
• Rheumatoid Arthritis 25%
• Safety Outcomes 25%
• Primary Reconstruction 25%
• Reoperation Rate 25%
• Multi-centered 25%
• Long-term Efficacy 25%
• Sjögren's Syndrome 25%
• Scleroderma 25%
• Stillbirth 25%
• Under-five 25%
• Operative Indication 25%
• Patient-level Data 25%
• Conclusive Evidence 25%
• Reasons for Reoperation 25%
• Revision Reconstruction 25%
• Implant-related Complications 25%
• Implant Outcome 25%
• Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) 25%
• Revision Augmentation 25%
• Surgeon Decision-making 25%
• United States Food 25%
• Reproductive Outcome 25%
• Silicone Breast Implants 25%
• Imaging Surveillance 25%
• Saline Implants 25%

Medicine and Dentistry

• Implant 100%
• Breast Implant 100%
• Reoperation 28%
• Capsular Contracture 28%
• Standardized Incidence Ratio 28%
• Surgeon 14%
• Melanoma 14%
• Magnetic Resonance Imaging 14%
• Decision Making 14%
• Anaplastic Large Cell Lymphoma 14%
• Table Salt 14%
• Inflammatory Arthritis 14%
• Rheumatoid Arthritis 14%
• Cohort Analysis 14%
• Sjoegren Syndrome 14%
• Stillbirth 14%
• Promethazine 14%
• Scleroderma 14%
• Automutilation 14%
• Reproductive Outcome 14%